Post by ProBioGen AG

A common challenge in poxvirus vaccine development: balancing speed, yield, and manufacturing stability. The AGE1.CR.ReX® cell line, together with the TetherexX™ System enable high-titer, stable recombinant MVA generation with increased process robustness. Dr. Ingo Jordan, Vice President of Vaccine Strategies at ProBioGen, on the platform enabling rapid and robust poxvirus-based vaccine development. 💡Learn more: https://lnkd.in/gVc3B__X